BridgeBio Highlights Attruby Data Showing Lower Hospitalization Risk In ATTR-CM At HFSA 2026
BridgeBio Pharma (BBIO) presented data at HFSA 2026 showing acoramidis reduced hospitalization risk in ATTR-CM patients. The study compared 910 acoramidis-treated patients with 1,774 tafamidis-treated patients, finding a 18% lower risk of composite endpoints (p<0.01) and 27% lower cardiovascular hospitalization risk (p<0.001). BBIO stock closed at $65.35, up 0.48%.
How this was made
The 30-second read
Why it matters
The key incremental trading signal is the reported statistically significant reduction in hospitalization burden and a composite endpoint versus tafamidis using Epic COSMOS propensity-matched cohorts, plus supportive post hoc findings from ATTRibute-CM.
Market read
Traders may reassess acoramidis’s competitive efficacy on hospitalization-related outcomes versus tafamidis, which can influence biotech valuation and positioning narratives.
What to watch
The article notes death differences were not statistically significant in the composite analysis, and benefits rely on propensity matching and specific database definitions of hospitalization and diuretic intensification.
Background
BridgeBio’s acoramidis (marketed as Attruby in the US and BEYONTTRA in multiple regions) is being evaluated in ATTR-CM against tafamidis, with new analyses presented at HFSA 2026.
Ticker impact
BridgeBio says acoramidis (ATTR-CM) showed statistically significant lower composite death and hospitalization risk versus tafamidis in Epic COSMOS propensity-matched data.
Likely upward bias as traders price improved efficacy on clinically meaningful endpoints and hospital burden versus tafamidis.
The article provides multiple statistically significant reductions in hospitalization-related endpoints and a survival trend, but it is still conference/disclosed analyses rather than a new FDA action or trial readout with fresh primary endpoints.
Market effects
Reinforces competitive positioning in transthyretin amyloid cardiomyopathy, potentially affecting sentiment across ATTR stabilizer peers.
Limited direct regional spillover; primarily US biotech sentiment tied to conference data.
Moderate, as tafamidis is a global comparator and the data may influence international investor views on ATTR-CM treatment efficacy.
Counterpoint
Real-world database and post hoc analyses may be more prone to residual confounding than randomized endpoints, so the market may overreact to statistically significant but non-primary comparisons.
Key entities
- companyBridgeBio Pharma, Inc.
Subject of the article; presents new real-world and Phase 3 analyses for acoramidis in ATTR-CM.
- drugAcoramidis
ATTR-CM transthyretin stabiliser discussed, associated with lower hospitalization risk versus tafamidis in the reported analyses.
- drugTafamidis
Pfizer’s oral ATTR-CM therapy used as the comparator in the Epic COSMOS propensity-matched analysis.
- data_sourceEpic COSMOS
US electronic record database used for the propensity score-matched real-world analysis.
- eventHeart Failure Society of America (HFSA) Annual Scientific Meeting 2026
Conference venue where the new analyses were presented.
